跳轉至內容
Merck
全部照片(1)

文件

D2975000

阿霉素 盐酸盐

European Pharmacopoeia (EP) Reference Standard

同義詞:

DOX, 多柔比星® 盐酸盐, 羟基柔红霉素 盐酸盐

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C27H29NO11 · HCl
CAS號碼:
分子量::
579.98
Beilstein:
4229251
EC號碼:
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

doxorubicin

製造商/商標名

EDQM

mp

216 °C (dec.) (lit.)

應用

pharmaceutical (small molecule)

格式

neat

SMILES 字串

Cl[H].COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO

InChI

1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22+,27-;/m0./s1

InChI 密鑰

MWWSFMDVAYGXBV-RUELKSSGSA-N

基因資訊

human ... TOP2A(7153)

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets, has been developed and issued under the Authority of the Issuing Pharmacopoeia.

For further information and support please go to the website of the issuing Pharmacopoeia.

Produced by certain strains of Streptomyces coeruleorubidus or Streptomyces peucetius or obtained by any other means.

應用

This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia. Their suitability for any other use is not guaranteed and is the sole responsibility of the user. This standard is not intended for human or animal use.
Established for the preparation of the below-given solutions as per European Pharmacopoeia:
  • Reference solutions (b) and (c) in the testing of related substances in daunorubicin hydrochloride using liquid chromatography (General text 2.2.29), according to the monograph 0662
  • Reference solutions (a) and (c) to test related substances in doxorubicin hydrochloride using liquid chromatography (General text 2.2.29), according to the monograph 0714
  • Reference solutions (b) and (c) in the testing of related substances in epirubicin hydrochloride using liquid chromatography (General text 2.2.29), according to the monograph 1590

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Health hazardExclamation mark

訊號詞

Danger

危險分類

Acute Tox. 4 Oral - Carc. 1B - Muta. 1B - Repr. 1B

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


Choose from one of the most recent versions:

分析證明 (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Doxorubicin hydrochloride
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 2471-2472 (2008)
Daunorubicin hydrochloride
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 2343-2344 (2008)
Epirubicin hydrochloride
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 4974-4975 (2021)
Maide Gökçe Bekaroğlu et al.
Materials science & engineering. C, Materials for biological applications, 103, 109838-109838 (2019-07-28)
The objective of the study was to obtain multifunctional core shell nanostructures of superparamagnetic iron oxide nanoparticles (Fe3O4) coated with various ionic biopolymers that can optimize toxicity to healthy cells, colloidal instabilities and drug loading capacities. These nanostructures can also
C Main et al.
Health technology assessment (Winchester, England), 10(9), 1-132 (2006-03-21)
To examine the clinical effectiveness and cost-effectiveness of intravenous formulations of topotecan monotherapy, pegylated liposomal doxorubicin hydorocholoride (PLDH) monotherapy and paclitaxel used alone or in combination with a platinum-based compound for the second-line or subsequent treatment of advanced ovarian cancer.

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務